PATENT

FEB 2 0 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

AD OLUFUNMILAYO I. OLOPADE

Serial No.: 08/674,311

Filed: JULY 1, 1996

For: METHYLTHIOADENOSINE

PHOSPHORYLASE COMPOSITIONS AND METHODS OF USE IN THE DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISORDERS Group Art Unit: 1807

Examiner: AMY ATZEL

Atty. Dkt. No.: ARSB:509/KIT

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

February 17, 1998

Date

Signature

DECLARATION OF OLUFUNMILAYO I. OLOPADE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

I, OLUFUNMILAYO I. OLOPADE, HEREBY DECLARE AS FOLLOWS:

- 1. I am the inventor of the subject matter disclosed and claimed in the referenced patent application.
- 2 I understand that the Patent and Trademark Office examiner in charge of examining this application has cited against my application the following articles:
 - a) Porterfield, Bruce W., Olopade, Olufunmilayo I., Rowley, Janet D., and Diaz, Manuel O. "Analysis of Tumor Suppressor Gene on Human Chromosome 9 in Mouse X Human Somatic Cell Hybrids", *Somatic Cell and Molecular Genetics*, Vol. 20, No. 5, 391-400, (1994).

- b) Bohlander, Stefan K., Dreyling, Martin H., Hagos, Fitsum, Sveen, Lise, Olopade, Olufunmilayo I., and Diaz, Manuel O., "Mapping a Putative Tumor Suppressor Gene on Chromosome 9 Bands p21-p22 with Microdissection Probes", *Genomics* 24, 211-217 (1994).
- c) Dreyling, Martin H., Bohlander, S. K., Adeyanju, M. O., and Olopage, O. I., "Detection of CDKN2 Deletions in Tumor Cell Lines and Primary Glioma by Interphase Fluorescence *in Situ* Hybridization", *Cancer Research* 55, 984-988, (March 1, 1995).
- d) Olopade, Olufunmilayo I., Pomykala, Helen M., Hagos, Fitsum, Sveen, Lise W., Espinosa III, Rafael, Dreyling, Martin H., Gursky, Susan, Stadler, Walter M., Le Beau, Michelle M., and Bohlander Stefan K., "Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21", *Proc. Natl. Acad. Sci. USA*, Vol. 92, 6489-6493, (July, 1995).
- 3. Martin H. Dreyling was a Post Doctoral Fellow, working under my direction and guidance. He did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 4. M. O. Adeyanju was a Post Doctoral Fellow, working under my direction and guidance. He did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 5. Fitsum Hagos was a Research Technician, working under my direction and guidance. He did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 6. Lise W. Sveen was a Research Technician, working under my direction and guidance. He did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 7. Manuel O. Diaz was a faculty member and my former research mentor. He left the University of Chicago and did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 8. Helen M. Pomykala was a Research Technician, working under my direction and guidance. She did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 9. Rafael Espinosa, III, was a Research Technician, working under my direction and guidance. He did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 10. Susan Gursky was a Graduate Student, working under my direction and guidance. She did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.

- 11. Walter M. Stadler was a Post Doctoral Fellow, working under my direction and guidance. He did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 12. Michelle Le Beau was a faculty member at The University of Chicago. She did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- 13. Bruce W. Porterfield was a Graduate Student, working under Dr. Rowley's direction and guidance. He did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- Janet D. Rowley was a faculty member and former research mentor. She did not 14. participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- Stefan K. Bohlander was a Post Doctoral Fellow and later promoted as faculty 15. member. Dr. Bohlander participated in general discussions; however, he did not participate in the conception or reduction to practice of any of the subject matter disclosed and claimed in the referenced patent application.
- The concept of isolating and characterizing the entire MTAP gene was conceived 16. by Olufunmilayo Olopade and reduced to practice under the guidance and direction of Olufunmilayo I. Olopade.
- I hereby declare that all statements made of my own knowledge are true and all 17. statements made on information are believed to be true and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.